ELDEPRYL selegiline hydrochloride capsule

Ország: Egyesült Államok

Nyelv: angol

Forrás: NLM (National Library of Medicine)

Aktív összetevők:

SELEGILINE HYDROCHLORIDE (UNII: 6W731X367Q) (SELEGILINE - UNII:2K1V7GP655)

Beszerezhető a:

Mylan Specialty L.P.

INN (nemzetközi neve):

SELEGILINE HYDROCHLORIDE

Összetétel:

SELEGILINE HYDROCHLORIDE 5 mg

Recept típusa:

PRESCRIPTION DRUG

Engedélyezési státusz:

New Drug Application

Termékjellemzők

ELDEPRYL- SELEGILINE HYDROCHLORIDE CAPSULE
MYLAN SPECIALTY L.P.
----------
DESCRIPTION
ELDEPRYL (selegiline hydrochloride) is a levorotatory acetylenic
derivative of phenethylamine. It is
commonly referred to in the clinical and pharmacological literature as
l-deprenyl.
The chemical name is:
(R)-(-)-_N_,2-dimethyl-_N_-2-propynylphenethylamine hydrochloride. It
is a white to
near white crystalline powder, freely soluble in water, chloroform,
and methanol, and has a molecular
weight of 223.75. The structural formula is as follows:
Each aqua blue capsule is band imprinted with the Somerset logo on the
cap and "Eldepryl 5 mg" on the
body. Each capsule contains 5 mg selegiline hydrochloride, USP.
Inactive ingredients are anhydrous
citric acid, lactose, magnesium stearate, and microcrystalline
cellulose.
CLINICAL PHARMACOLOGY
The mechanisms accounting for selegiline's beneficial adjunctive
action in the treatment of Parkinson's
disease are not fully understood. Inhibition of monoamine oxidase,
type B, activity is generally
considered to be of primary importance; in addition, there is evidence
that selegiline may act through
other mechanisms to increase dopaminergic activity.
Selegiline is best known as an irreversible inhibitor of monoamine
oxidase (MAO), an intracellular
enzyme associated with the outer membrane of mitochondria. Selegiline
inhibits MAO by acting as a
'suicide' substrate for the enzyme; that is, it is converted by MAO to
an active moiety which combines
irreversibly with the active site and/or the enzyme's essential FAD
cofactor. Because selegiline has
greater affinity for type B rather than for type A active sites, it
can serve as a selective inhibitor of
MAO type B if it is administered at the recommended dose.
MAOs are widely distributed throughout the body; their concentration
is especially high in liver,
kidney, stomach, intestinal wall, and brain. MAOs are currently
subclassified into two types, A and B,
which differ in their substrate specificity and tissue distribution.
In humans, intestinal MAO